Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.35 |
| ▸ | CTSS | P25774 | 3/20 | 0.35 |
| ▸ | GRN | P28799 | 3/20 | 0.35 |
| ▸ | SORT1 | Q99523 | 3/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 7/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 2/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4835405 | 0.85 | CTSK (0.49) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL4835423 | 0.85 | CTSK (0.49) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL4837541 | 0.85 | CTSK (0.49) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL29683039 | 0.82 | CTSK (0.50) | CTSKCTSS | |
| SCHEMBL9257529 | 0.81 | CTSK (0.45) | CTSKCTSSGRNSORT1MEN1 | |
| SCHEMBL6193659 | 0.77 | CTSK (0.42) | CTSKCTSS | |
| SCHEMBL14589035 | 0.77 | CTSK (0.42) | CTSKCTSS | |
| SCHEMBL4836398 | 0.75 | CTSK (0.45) | CTSKCTSS | |
| SCHEMBL4407907 | 0.73 | SIRT2 (0.53) | CTSKCTSSPPARAPPARG | |
| SCHEMBL14567484 | 0.73 | SIRT2 (0.53) | CTSKCTSSPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6936606-B2 | Cyanoamido-containing heterocyclic compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| US-20040063679-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063679-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | CTSK 2/4885CTSS 1/4885GRN 2557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.